Abstract:Lysine-specific demethylase 4 A (KDM4A, also named JMJD2A, KIA0677, or JHDM3A) is a demethylase that can remove methyl groups from histones H3K9me2/3, H3K36me2/3, and H1.4K26me2/me3. Accumulating evidence suggests that KDM4A is not only involved in body homeostasis (such as cell proliferation, migration and differentiation, and tissue development) but also associated with multiple human diseases, especially cancers. Recently, an increasing number of studies have shown that pharmacological inhibition of KDM4A significantly attenuates tumor progression in vitro and in vivo in a range of solid tumors and acute myeloid leukemia. Although there are several reviews on the roles of the KDM4 subfamily in cancer development and therapy, all of them only briefly introduce the roles of KDM4A in cancer without systematically summarizing the specific mechanisms of KDM4A in various physiological and pathological processes, especially in tumorigenesis, which greatly limits advances in the understanding of the roles of KDM4A in a variety of cancers, discovering targeted selective KDM4A inhibitors, and exploring the adaptive profiles of KDM4A antagonists. Herein, we present the structure and functions of KDM4A, simply outline the functions of KDM4A in homeostasis and non-cancer diseases, summarize the role of KDM4A and its distinct target genes in the development of a variety of cancers, systematically classify KDM4A inhibitors, summarize the difficulties encountered in the research of KDM4A and the discovery of related drugs, and provide the corresponding solutions, which would contribute to understanding the recent research trends on KDM4A and advancing the progression of KDM4A as a drug target in cancer therapy.

Pharmacological inhibition of KDM5A for cancer treatment

Targeting Histone Demethylase KDM5B for Cancer Treatment.

Targeting histone demethylase KDM5B for cancer treatment

Histone Demethylase Lysine Demethylase 5B in Development and Cancer

The emerging role of KDM5A in human cancer

The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumorigenesis and therapeutic opportunities

Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines

An Inhibitor of KDM5 Demethylases Reduces Survival of Drug-Tolerant Cancer Cells.

Pharmacological Inhibition of LSD1 for Cancer Treatment

Small Molecule KDM4s Inhibitors As Anti-Cancer Agents

Advances in Histone Demethylase KDM3A as a Cancer Therapeutic Target

Selective Inhibition of Lysine‐Specific Demethylase 5A (KDM5A) Using a Rhodium(III) Complex for Triple‐Negative Breast Cancer Therapy

Discovery of Pyrazole Derivatives As Cellular Active Inhibitors of Histone Lysine Specific Demethylase 5B (KDM5B/JARID1B).

Progress in Research of KDM5C in Human Tumors

KDM4B: A promising oncology therapeutic target

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

KDM5 family as therapeutic targets in breast cancer: Pathogenesis and therapeutic opportunities and challenges

Lysine-specific demethylase 7A (KDM7A): A potential target for disease therapy

The role and prospect of lysine-specific demethylases in cancer chemoresistance

Novel Insights into Histone Lysine Methyltransferases in Cancer Therapy: from Epigenetic Regulation to Selective Drugs

Function of Histone Demethylasehistone Lysine-Specific Demethylase 1A in Tumor Initiation and Progression